Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

RFK Jr. and Influencers Bash Seed Oils, Baffling Nutrition Scientists

Until recently, most Americans had never heard the term “seed oils,” even though they’ve likely cooked with and consumed them for decades. It’s the catchy

March 9, 2025

Telehealth, Default Orders Show Promise in Palliative Care

A palliative telecare intervention improved quality of life for patients with chronic obstructive pulmonary disease (COPD), heart failure (HF), and interstitial lung disease (ILD), the

January 18, 2024

Long-term hormone therapy proves valuable for older women

The Menopause Society’s 2022 Hormone Therapy Position Statement advises that women aged older than 65 years can continue using hormone therapy (HT) with appropriate counseling

September 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.